Biochemical assays are commonly used to assess how organic compounds impact the activity of a protein of interest (POI). ZoBio frequently employs biochemical assays to validate compounds that have been identified as interacting with the POI through orthogonal biophysical assays like Surface Plasmon Resonance (SPR) and Nuclear Magnetic Resonance (NMR). To enhance the efficiency and reliability of the biochemical assay workflow, ZoBio has purchased a Dragonfly™ Discovery, a valuable tool known for its ability to significantly improve assay performance by facilitating high-throughput…

Recent years have seen a surge of interest in the use of covalent compounds in small molecule drug discovery. Much of this interest has been driven by the success of covalent compounds for “undruggable” targets such as kRAS. While it is relatively easy to buy or build a library of cysteine reactive compounds and screen them using mass spectrometry (MS), does this really provide all the information to decide whether a “hit” is a good starting point for a drug discovery campaign?
Typically, a covalent campaign starts with screening a library for conjugation…